Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Medscape CME Activity

Medscape, LLC is pleased to provide online continuing medical education (CME) for selected journal articles, allowing clinicians the opportunity to earn CME credit. In support of improving patient care, these activities have been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME credit is available for one year after publication.

Active CME Articles


Expires 1/23/2024
Medscape CME Activity
Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021 [PDF - 2.14 MB - 8 pages]
H. Lorenzo Juanes et al.

Crimean-Congo hemorrhagic fever (CCHF) is a viral infectious disease for which distribution of the main vector, Hyalomma spp. ticks, is expanding. We analyzed all 10 cases of CCHF diagnosed in Spain during 2013–2021; case-patient median age was 56.5 years, and 7 were men. We identified CCHF virus genotypes III and V. Six case-patients acquired the infection in urban areas. Sixty percent of patients were infected in summer and 40% in spring. Two patients met criteria for hemophagocytic syndrome. Seven patients survived. The epidemiologic pattern of CCHF in Spain is based on occasional cases with an elevated mortality rate. Genotype III and, to a less extent also genotype V, CCHF circulates in humans in a common geographic area in Spain. Those data suggest that the expansion pathways are complex and may change over time. Physicians should remain alert to the possibility of new CCHF cases.

EID Lorenzo Juanes H, Carbonell C, Sendra B, López-Bernus A, Bahamonde A, Orfao A, et al. Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021. Emerg Infect Dis. 2023;29(2):252-259. https://doi.org/10.3201/eid2902.220677
AMA Lorenzo Juanes H, Carbonell C, Sendra B, et al. Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021. Emerging Infectious Diseases. 2023;29(2):252-259. doi:10.3201/eid2902.220677.
APA Lorenzo Juanes, H., Carbonell, C., Sendra, B., López-Bernus, A., Bahamonde, A., Orfao, A....Belhassen-García, M. (2023). Crimean-Congo Hemorrhagic Fever, Spain, 2013–2021. Emerging Infectious Diseases, 29(2), 252-259. https://doi.org/10.3201/eid2902.220677.

Expires 1/20/2024
Medscape CME Activity
Infant Botulism, Israel, 2007–2021 [PDF - 463 KB - 7 pages]
B. Goldberg et al.

Infant botulism (IB) is an intestinal toxemia that manifests as descending paralysis, constipation, and, in some cases, respiratory failure. Laboratory-confirmed IB cases are rare, and recent data in Israel are lacking. We conducted a national multicenter retrospective study of laboratory-confirmed IB cases reported in Israel during 2007–2021. A total of 8 cases were reported during the study period. During 2019–2021, incidence may have increased because of a cluster of 5 cases. Infant median age for diagnosis was 6.5 months, older than previously reported (3 months). Most cases occurred during March–July. Honey consumption was reported in 1 case, and possible environmental risk factors (living nearby rural or construction areas, dust exposure, and having a father who works as a farmer) were reported in 6 cases. Although IB is rare, its incidence in Israel may have increased over recent years, and its epidemiology and risk factors differ from cases reported previously in Israel.

EID Goldberg B, Danino D, Levinsky Y, Levy I, Straussberg R, Dabaja-Younis H, et al. Infant Botulism, Israel, 2007–2021. Emerg Infect Dis. 2023;29(2):235-241. https://doi.org/10.3201/eid2902.220991
AMA Goldberg B, Danino D, Levinsky Y, et al. Infant Botulism, Israel, 2007–2021. Emerging Infectious Diseases. 2023;29(2):235-241. doi:10.3201/eid2902.220991.
APA Goldberg, B., Danino, D., Levinsky, Y., Levy, I., Straussberg, R., Dabaja-Younis, H....Scheuerman, O. (2023). Infant Botulism, Israel, 2007–2021. Emerging Infectious Diseases, 29(2), 235-241. https://doi.org/10.3201/eid2902.220991.

Expires 12/21/2023
Medscape CME Activity
Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States [PDF - 1.65 MB - 7 pages]
M. K. Roe et al.

The emergence of SARS-CoV-2 and the worldwide COVID-19 pandemic triggered considerable attention to the emergence and evolution of novel human pathogens. Bourbon virus (BRBV) was first discovered in 2014 in Bourbon County, Kansas, USA. Since its initial discovery, several cases of BRBV infection in humans have been identified in Kansas, Oklahoma, and Missouri. BRBV is classified within the Thogotovirus genus; these negative-strand RNA viruses appear to be transmitted by ticks, and much of their biology remains unknown. In this review, we describe the emergence, virology, geographic range and ecology, and human disease caused by BRBV and discuss potential treatments for active BRBV infections. This virus and other emerging viral pathogens remain key public health concerns and require continued surveillance and study to mitigate human exposure and disease.

EID Roe MK, Huffman ER, Batista YS, Papadeas GG, Kastelitz SR, Restivo AM, et al. Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States. Emerg Infect Dis. 2023;29(1):1-7. https://doi.org/10.3201/eid2901.212295
AMA Roe MK, Huffman ER, Batista YS, et al. Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States. Emerging Infectious Diseases. 2023;29(1):1-7. doi:10.3201/eid2901.212295.
APA Roe, M. K., Huffman, E. R., Batista, Y. S., Papadeas, G. G., Kastelitz, S. R., Restivo, A. M....Stobart, C. C. (2023). Comprehensive Review of Emergence and Virology of Tickborne Bourbon Virus in the United States. Emerging Infectious Diseases, 29(1), 1-7. https://doi.org/10.3201/eid2901.212295.

Expires 12/19/2023
Medscape CME Activity
Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India [PDF - 629 KB - 12 pages]
V. Muthu et al.

We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM.

EID Muthu V, Agarwal R, Rudramurthy S, Thangaraju D, Shevkani M, Patel AK, et al. Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India. Emerg Infect Dis. 2023;29(1):8-19. https://doi.org/10.3201/eid2901.220926
AMA Muthu V, Agarwal R, Rudramurthy S, et al. Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India. Emerging Infectious Diseases. 2023;29(1):8-19. doi:10.3201/eid2901.220926.
APA Muthu, V., Agarwal, R., Rudramurthy, S., Thangaraju, D., Shevkani, M., Patel, A. K....Chakrabarti, A. (2023). Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India. Emerging Infectious Diseases, 29(1), 8-19. https://doi.org/10.3201/eid2901.220926.

Expires 11/18/2023
Medscape CME Activity
Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019 [PDF - 666 KB - 7 pages]
F. Hoefler et al.

Noncholera vibriosis is a rare, opportunistic bacterial infection caused by Vibrio spp. other than V. cholerae O1/O139 and diagnosed mainly during the hot summer months in patients after seaside activities. Detailed knowledge of circulating pathogenic strains and heterogeneities in infection outcomes and disease dynamics may help in patient management. We conducted a multicenter case-series study documenting Vibrio infections in 67 patients from 8 hospitals in the Bay of Biscay, France, over a 19-year period. Infections were mainly caused by V. alginolyticus (34%), V. parahaemolyticus (30%), non-O1/O139 V. cholerae (15%), and V. vulnificus (10%). Drug-susceptibility testing revealed intermediate and resistant strains to penicillins and first-generation cephalosporins. The acute infections (e.g., those involving digestive disorder, cellulitis, osteitis, pneumonia, and endocarditis) led to a life-threatening event (septic shock), amputation, or death in 36% of patients. Physicians may need to add vibriosis to their list of infections to assess in patients with associated risk factors.

EID Hoefler F, Pouget-Abadie X, Roncato-Saberan M, Lemarié R, Takoudju E, Raffi F, et al. Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019. Emerg Infect Dis. 2022;28(12):2367-2373. https://doi.org/10.3201/eid2812.220748
AMA Hoefler F, Pouget-Abadie X, Roncato-Saberan M, et al. Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019. Emerging Infectious Diseases. 2022;28(12):2367-2373. doi:10.3201/eid2812.220748.
APA Hoefler, F., Pouget-Abadie, X., Roncato-Saberan, M., Lemarié, R., Takoudju, E., Raffi, F....Allix-Béguec, C. (2022). Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019. Emerging Infectious Diseases, 28(12), 2367-2373. https://doi.org/10.3201/eid2812.220748.

Expires 11/17/2023
Medscape CME Activity
Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China [PDF - 1.20 MB - 11 pages]
W. Zhang et al.

Acinetobacter baumannii is a nosocomial pathogen associated with severe illness and death. Glucocorticoid aerosol is a common inhalation therapy in patients receiving invasive mechanical ventilation. We conducted a prospective cohort study to analyze the association between glucocorticoid aerosol therapy and A. baumannii isolation from ventilator patients in China. Of 497 enrolled patients, 262 (52.7%) received glucocorticoid aerosol, and A. baumannii was isolated from 159 (32.0%). Glucocorticoid aerosol therapy was an independent risk factor for A. baumannii isolation (hazard ratio 1.5, 95% CI 1.02–2.28; p = 0.038). Patients receiving glucocorticoid aerosol had a higher cumulative hazard for A. baumannii isolation and analysis showed that glucocorticoid aerosol therapy increased A. baumannii isolation in most subpopulations. Glucocorticoid aerosol was not a direct risk factor for 30-day mortality, but A. baumannii isolation was independently associated with 30-day mortality in ventilator patients. Physicians should consider potential A. baumannii infection when prescribing glucocorticoid aerosol therapy.

EID Zhang W, Yin M, Li W, Xu N, Lu H, Qin W, et al. Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China. Emerg Infect Dis. 2022;28(12):2404. https://doi.org/10.3201/eid2812.220347
AMA Zhang W, Yin M, Li W, et al. Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China. Emerging Infectious Diseases. 2022;28(12):2404. doi:10.3201/eid2812.220347.
APA Zhang, W., Yin, M., Li, W., Xu, N., Lu, H., Qin, W....Wang, H. (2022). Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China. Emerging Infectious Diseases, 28(12), 2404. https://doi.org/10.3201/eid2812.220347.

Expires 10/19/2023
Medscape CME Activity
Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019 [PDF - 632 KB - 8 pages]
Y. Lee et al.

We investigated the proportion and characteristics of severe Corynebacterium striatum pneumonia in South Korea during 2014–2019. As part of an ongoing observational study of severe pneumonia among adult patients, we identified 27 severe C. striatum pneumonia cases. Most (70.4%) cases were hospital-acquired, and 51.9% of patients were immunocompromised. C. striatum cases among patients with severe hospital-acquired pneumonia (HAP) increased from 1.0% (2/200) during 2014–2015 to 5.4% (10/185) during 2018–2019, but methicillin-resistant Staphylococcus aureus (MRSA) infections among severe HAP cases decreased from 12.0% to 2.7% during the same timeframe. During 2018–2019, C. striatum was responsible for 13.3% of severe HAP cases from which bacterial pathogens were identified. The 90-day mortality rates were similarly high in the C. striatum and MRSA groups. C. striatum was a major cause of severe HAP and had high mortality rates. This pathogen is emerging as a possible cause for severe pneumonia, especially among immunocompromised patients.

EID Lee Y, Huh J, Hong S, Jung J, Kim M, Chong Y, et al. Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerg Infect Dis. 2022;28(11):2147-2154. https://doi.org/10.3201/eid2811.220273
AMA Lee Y, Huh J, Hong S, et al. Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerging Infectious Diseases. 2022;28(11):2147-2154. doi:10.3201/eid2811.220273.
APA Lee, Y., Huh, J., Hong, S., Jung, J., Kim, M., Chong, Y....Choi, S. (2022). Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerging Infectious Diseases, 28(11), 2147-2154. https://doi.org/10.3201/eid2811.220273.

Expires 10/18/2023
Medscape CME Activity
Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia [PDF - 2.28 MB - 10 pages]
J. Li et al.

A multispecies outbreak of Nocardia occurred among heart transplant recipients (HTR), but not lung transplant recipients (LTR), in Sydney, New South Wales, Australia, during 2018–2019. We performed a retrospective review of 23 HTR and LTR who had Nocardia spp. infections during June 2015–March 2021, compared risk factors for Nocardia infection, and evaluated climate conditions before, during, and after the period of the 2018–2019 outbreak. Compared with LTR, HTR had a shorter median time from transplant to Nocardia diagnosis, higher prevalence of diabetes, greater use of induction immunosuppression with basiliximab, and increased rates of cellular rejection before Nocardia diagnosis. During the outbreak, Sydney experienced the lowest monthly precipitation and driest surface levels compared with time periods directly before and after the outbreak. Increased immunosuppression of HTR compared with LTR, coupled with extreme weather conditions during 2018–2019, may explain this outbreak of Nocardia infections in HTR.

EID Li J, Lau C, Anderson N, Burrows F, Mirdad F, Carlos L, et al. Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerg Infect Dis. 2022;28(11):2155-2164. https://doi.org/10.3201/eid2811.220262
AMA Li J, Lau C, Anderson N, et al. Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerging Infectious Diseases. 2022;28(11):2155-2164. doi:10.3201/eid2811.220262.
APA Li, J., Lau, C., Anderson, N., Burrows, F., Mirdad, F., Carlos, L....Dharan, N. J. (2022). Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerging Infectious Diseases, 28(11), 2155-2164. https://doi.org/10.3201/eid2811.220262.

Expires 9/21/2023
Medscape CME Activity
Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019 [PDF - 8.04 MB - 15 pages]
E. Rayens et al.

Fungal infections cause substantial rates of illness and death. Interest in the association between demographic factors and fungal infections is increasing. We analyzed 2019 US hospital discharge data to assess factors associated with fungal infection diagnosis, including race and ethnicity and socioeconomic status. We found male patients were 1.5–3.5 times more likely to have invasive fungal infections diagnosed than were female patients. Compared with hospitalizations of non-Hispanic White patients, Black, Hispanic, and Native American patients had 1.4–5.9 times the rates of cryptococcosis, pneumocystosis, and coccidioidomycosis. Hospitalizations associated with lower-income areas had increased rates of all fungal infections, except aspergillosis. Compared with younger patients, fungal infection diagnosis rates, particularly for candidiasis, were elevated among persons >65 years of age. Our findings suggest that differences in fungal infection diagnostic rates are associated with demographic and socioeconomic factors and highlight an ongoing need for increased physician evaluation of risk for fungal infections.

EID Rayens E, Rayens M, Norris KA. Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019. Emerg Infect Dis. 2022;28(10):1955-1969. https://doi.org/10.3201/eid2810.220391
AMA Rayens E, Rayens M, Norris KA. Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019. Emerging Infectious Diseases. 2022;28(10):1955-1969. doi:10.3201/eid2810.220391.
APA Rayens, E., Rayens, M., & Norris, K. A. (2022). Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019. Emerging Infectious Diseases, 28(10), 1955-1969. https://doi.org/10.3201/eid2810.220391.

Expires 9/15/2023
Medscape CME Activity
Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980–2021 [PDF - 1.82 MB - 10 pages]
M. Elbaz et al.

Tick-borne encephalitis (TBE) is a viral infection of the central nervous system that occurs in many parts of Europe and Asia. Humans mainly acquire TBE through tick bites, but TBE occasionally is contracted through consuming unpasteurized milk products from viremic livestock. We describe cases of TBE acquired through alimentary transmission in Europe during the past 4 decades. We conducted a systematic review and meta-analysis of 410 foodborne TBE cases, mostly from a region in central and eastern Europe. Most cases were reported during the warmer months (April–August) and were associated with ingesting unpasteurized dairy products from goats. The median incubation period was short, 3.5 days, and neuroinvasive disease was common (38.9%). The clinical attack rate was 14% (95% CI 12%–16%), and we noted major heterogeneity. Vaccination programs and public awareness campaigns could reduce the number of persons affected by this potentially severe disease.

EID Elbaz M, Gadoth A, Shepshelovich D, Shasha D, Rudoler N, Paran Y. Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980–2021. Emerg Infect Dis. 2022;28(10):1945-1954. https://doi.org/10.3201/eid2810.220498
AMA Elbaz M, Gadoth A, Shepshelovich D, et al. Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980–2021. Emerging Infectious Diseases. 2022;28(10):1945-1954. doi:10.3201/eid2810.220498.
APA Elbaz, M., Gadoth, A., Shepshelovich, D., Shasha, D., Rudoler, N., & Paran, Y. (2022). Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980–2021. Emerging Infectious Diseases, 28(10), 1945-1954. https://doi.org/10.3201/eid2810.220498.

Expires 8/22/2023
Medscape CME Activity
Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019 [PDF - 1.24 MB - 11 pages]
E. M. Dunne et al.

We investigated invasive group A Streptococcus epidemiology in Idaho, USA, during 2008–2019 using surveillance data, medical record review, and emm (M protein gene) typing results. Incidence increased from 1.04 to 4.76 cases/100,000 persons during 2008–2019. emm 1, 12, 28, 11, and 4 were the most common types, and 2 outbreaks were identified. We examined changes in distribution of clinical syndrome, patient demographics, and risk factors by comparing 2008–2013 baseline with 2014–2019 data. Incidence was higher among all age groups during 2014–2019. Streptococcal toxic shock syndrome increased from 0% to 6.4% of cases (p = 0.02). We identified no differences in distribution of demographic or risk factors between periods. Results indicated that invasive group A Streptococcus is increasing among the general population of Idaho. Ongoing surveillance of state-level invasive group A Streptococcus cases could help identify outbreaks, track regional trends in incidence, and monitor circulating emm types.

EID Dunne EM, Hutton S, Peterson E, Blackstock AJ, Hahn CG, Turner K, et al. Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019. Emerg Infect Dis. 2022;28(9):1785-1795. https://doi.org/10.3201/eid2809.212129
AMA Dunne EM, Hutton S, Peterson E, et al. Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019. Emerging Infectious Diseases. 2022;28(9):1785-1795. doi:10.3201/eid2809.212129.
APA Dunne, E. M., Hutton, S., Peterson, E., Blackstock, A. J., Hahn, C. G., Turner, K....Carter, K. K. (2022). Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019. Emerging Infectious Diseases, 28(9), 1785-1795. https://doi.org/10.3201/eid2809.212129.

Expires 8/15/2023
Medscape CME Activity
Fetal Loss and Preterm Birth Caused by Intraamniotic Haemophilus influenzae Infection, New Zealand [PDF - 826 KB - 8 pages]
T. Hills et al.

Invasive Haemophilus influenzae infection during pregnancy can cause preterm birth and fetal loss, but the mechanism is unclear. We investigated 54 cases of pregnancy-associated invasive H. influenzae disease in 52 unique pregnancies in the Auckland region of New Zealand during October 1, 2008‒September 30, 2018. Intraamniotic infection was identified in 36 (66.7%) of 54 cases. Outcome data were available for 48 pregnancies. Adverse pregnancy outcomes, defined as fetal loss, preterm birth, or the birth of an infant requiring intensive/special care unit admission, occurred in 45 (93.8%) of 48 (pregnancies. Fetal loss occurred in 17 (35.4%) of 48 pregnancies, before 24 weeks’ gestation in 13 cases, and at >24 weeks’ gestation in 4 cases. The overall incidence of pregnancy-associated invasive H. influenzae disease was 19.9 cases/100,000 births, which exceeded the reported incidence of pregnancy-associated listeriosis in New Zealand. We also observed higher rates in younger women and women of Māori ethnicity.

EID Hills T, Sharpe C, Wong T, Cutfield T, Lee A, McBride S, et al. Fetal Loss and Preterm Birth Caused by Intraamniotic Haemophilus influenzae Infection, New Zealand. Emerg Infect Dis. 2022;28(9):1747-1754. https://doi.org/10.3201/eid2809.220313
AMA Hills T, Sharpe C, Wong T, et al. Fetal Loss and Preterm Birth Caused by Intraamniotic Haemophilus influenzae Infection, New Zealand. Emerging Infectious Diseases. 2022;28(9):1747-1754. doi:10.3201/eid2809.220313.
APA Hills, T., Sharpe, C., Wong, T., Cutfield, T., Lee, A., McBride, S....Thomas, M. (2022). Fetal Loss and Preterm Birth Caused by Intraamniotic Haemophilus influenzae Infection, New Zealand. Emerging Infectious Diseases, 28(9), 1747-1754. https://doi.org/10.3201/eid2809.220313.

Expires 7/20/2023
Medscape CME Activity
Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches [PDF - 673 KB - 11 pages]
L. E. Manhart et al.

Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.

EID Manhart LE, Geisler WM, Bradshaw CS, Jensen JS, Martin DH. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerg Infect Dis. 2022;28(8):1-11. https://doi.org/10.3201/eid2808.220094
AMA Manhart LE, Geisler WM, Bradshaw CS, et al. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases. 2022;28(8):1-11. doi:10.3201/eid2808.220094.
APA Manhart, L. E., Geisler, W. M., Bradshaw, C. S., Jensen, J. S., & Martin, D. H. (2022). Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases, 28(8), 1-11. https://doi.org/10.3201/eid2808.220094.

Expires 6/17/2023
Medscape CME Activity
Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States [PDF - 498 KB - 8 pages]
A. Irish et al.

We combined American Community Survey data with age-specific Trypanosoma cruzi prevalence derived from US surveys and World Health Organization reports to yield estimates of Chagas disease in the United States, which we mapped at the local level. In addition, we used blood donor data to estimate the relative prevalence of autochthonous T. cruzi infection. Our estimates indicate that 288,000 infected persons, including 57,000 Chagas cardiomyopathy patients and 43,000 infected reproductive-age women, currently live in the United States; 22–108 congenital infections occur annually. We estimated ≈10,000 prevalent cases of locally acquired T. cruzi infection. Mapping shows marked geographic heterogeneity of T. cruzi prevalence and illness. Reliable demographic and geographic data are key to guiding prevention and management of Chagas disease. Population-based surveys in high prevalence areas could improve the evidence base for future estimates. Knowledge of the demographics and geographic distribution of affected persons may aid practitioners in recognizing Chagas disease.

EID Irish A, Whitman JD, Clark EH, Marcus R, Bern C. Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States. Emerg Infect Dis. 2022;28(7):1313-1320. https://doi.org/10.3201/eid2807.212221
AMA Irish A, Whitman JD, Clark EH, et al. Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States. Emerging Infectious Diseases. 2022;28(7):1313-1320. doi:10.3201/eid2807.212221.
APA Irish, A., Whitman, J. D., Clark, E. H., Marcus, R., & Bern, C. (2022). Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States. Emerging Infectious Diseases, 28(7), 1313-1320. https://doi.org/10.3201/eid2807.212221.

Expires 6/16/2023
Medscape CME Activity
Natural History of and Dynamic Changes in Clinical Manifestation, Serology, and Treatment of Brucellosis, China [PDF - 1.63 MB - 6 pages]
H. Wang et al.

Serum agglutination test plus exposure history were used to diagnose most cases of human brucellosis in 2 China provinces. After appropriate treatment, 13.3% of acute brucellosis cases progressed to chronic disease; arthritis was an early predictor. Seropositivity can persist after symptoms disappear, which might cause physicians to subjectively extend therapeutic regimens.

EID Wang H, Liu H, Zhang Q, Lu X, Li D, Zhang H, et al. Natural History of and Dynamic Changes in Clinical Manifestation, Serology, and Treatment of Brucellosis, China. Emerg Infect Dis. 2022;28(7):1460-1465. https://doi.org/10.3201/eid2807.211766
AMA Wang H, Liu H, Zhang Q, et al. Natural History of and Dynamic Changes in Clinical Manifestation, Serology, and Treatment of Brucellosis, China. Emerging Infectious Diseases. 2022;28(7):1460-1465. doi:10.3201/eid2807.211766.
APA Wang, H., Liu, H., Zhang, Q., Lu, X., Li, D., Zhang, H....Zhang, W. (2022). Natural History of and Dynamic Changes in Clinical Manifestation, Serology, and Treatment of Brucellosis, China. Emerging Infectious Diseases, 28(7), 1460-1465. https://doi.org/10.3201/eid2807.211766.

Expires 5/23/2023
Medscape CME Activity
Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020 [PDF - 1.11 MB - 7 pages]
T. Gaufin et al.

Annually, Shigella spp. cause ≈188 million cases of diarrheal disease globally, including 500,000 cases in the United States; rates of antimicrobial resistance are increasing. To determine antimicrobial resistance and risk factors in San Diego, California, USA, we retrospectively reviewed cases of diarrheal disease caused by Shigella flexneri and S. sonnei diagnosed during 2017–2020. Of 128 evaluable cases, S. flexneri was slightly more common than S. sonnei; most cases were in persons who were gay or bisexual cisgender men, were living with HIV, were unhoused, or used methamphetamines. Overall, rates of resistance to azithromycin, fluoroquinolones, ampicillin, and trimethoprim/sulfamethoxazole (TMP/SMX) were comparable to the most recent national data reported from the Centers for Disease Control and Prevention; 55% of isolates were resistant to azithromycin, 23% to fluoroquinolones, 70% to ampicillin, and 83% to TMP/SMX. The rates that we found for TMP/SMX were slightly higher than those in national data.

EID Gaufin T, Blumenthal J, Ramirez-Sanchez C, Mehta S, Pride DT, Fierer J, et al. Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020. Emerg Infect Dis. 2022;28(6):1110-1116. https://doi.org/10.3201/eid2806.220131
AMA Gaufin T, Blumenthal J, Ramirez-Sanchez C, et al. Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020. Emerging Infectious Diseases. 2022;28(6):1110-1116. doi:10.3201/eid2806.220131.
APA Gaufin, T., Blumenthal, J., Ramirez-Sanchez, C., Mehta, S., Pride, D. T., Fierer, J....Jenks, J. D. (2022). Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020. Emerging Infectious Diseases, 28(6), 1110-1116. https://doi.org/10.3201/eid2806.220131.

Expires 5/20/2023
Medscape CME Activity
Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA [PDF - 724 KB - 10 pages]
F. A. Ramadan et al.

Demographic and clinical indicators have been described to support identification of coccidioidomycosis; however, the interplay of these conditions has not been explored in a clinical setting. In 2019, we enrolled 392 participants in a cross-sectional study for suspected coccidioidomycosis in emergency departments and inpatient units in Coccidioides-endemic regions. We aimed to develop a predictive model among participants with suspected coccidioidomycosis. We applied a least absolute shrinkage and selection operator to specific coccidioidomycosis predictors and developed univariable and multivariable logistic regression models. Univariable models identified elevated eosinophil count as a statistically significant predictive feature of coccidioidomycosis in both inpatient and outpatient settings. Our multivariable outpatient model also identified rash (adjusted odds ratio 9.74 [95% CI 1.03–92.24]; p = 0.047) as a predictor. Our results suggest preliminary support for developing a coccidioidomycosis prediction model for use in clinical settings.

EID Ramadan FA, Ellingson KD, Canales RA, Bedrick EJ, Galgiani JN, Donovan FM. Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA. Emerg Infect Dis. 2022;28(6):1091-1100. https://doi.org/10.3201/eid2806.212311
AMA Ramadan FA, Ellingson KD, Canales RA, et al. Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA. Emerging Infectious Diseases. 2022;28(6):1091-1100. doi:10.3201/eid2806.212311.
APA Ramadan, F. A., Ellingson, K. D., Canales, R. A., Bedrick, E. J., Galgiani, J. N., & Donovan, F. M. (2022). Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA. Emerging Infectious Diseases, 28(6), 1091-1100. https://doi.org/10.3201/eid2806.212311.

Expires 4/18/2023
Medscape CME Activity
Invasive Group A Streptococcus Outbreaks Associated with Home Healthcare, England, 2018–2019 [PDF - 854 KB - 9 pages]
L. E. Nabarro et al.

Healthcare-associated invasive group A Streptococcus (iGAS) outbreaks are common worldwide, but only England has reported outbreaks associated with home healthcare (HHC). We describe 10 outbreaks during 2018–2019 in England. A total of 96 iGAS cases (range 2–39 per outbreak) and 28 deaths (case-fatality rate 29%) occurred. Outbreak duration ranged from 3–517 days; median time between sequential cases was 20.5 days (range 1–225 days). Outbreak identification was difficult, but emm typing and whole-genome sequencing improved detection. Network analyses indicated multiple potential transmission routes. Screening of 366 HHC workers from 9 outbreaks identified group A Streptococcus carriage in just 1 worker. Outbreak control required multiple interventions, including improved infection control, equipment decontamination, and antimicrobial prophylaxis for staff. Transmission routes and effective interventions are not yet clear, and iGAS outbreaks likely are underrecognized. To improve patient safety and reduce deaths, public health agencies should be aware of HHC-associated iGAS.

EID Nabarro LE, Brown CS, Balasegaram S, Decraene V, Elston J, Kapadia S, et al. Invasive Group A Streptococcus Outbreaks Associated with Home Healthcare, England, 2018–2019. Emerg Infect Dis. 2022;28(5):915-923. https://doi.org/10.3201/eid2805.211497
AMA Nabarro LE, Brown CS, Balasegaram S, et al. Invasive Group A Streptococcus Outbreaks Associated with Home Healthcare, England, 2018–2019. Emerging Infectious Diseases. 2022;28(5):915-923. doi:10.3201/eid2805.211497.
APA Nabarro, L. E., Brown, C. S., Balasegaram, S., Decraene, V., Elston, J., Kapadia, S....Lamagni, T. (2022). Invasive Group A Streptococcus Outbreaks Associated with Home Healthcare, England, 2018–2019. Emerging Infectious Diseases, 28(5), 915-923. https://doi.org/10.3201/eid2805.211497.

Expires 4/15/2023
Medscape CME Activity
Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015–2017 [PDF - 520 KB - 8 pages]
G. Peirano et al.

We describe the global molecular epidemiology of 229 carbapenemase-producing Escherichia coli in 36 countries during 2015–2017. Common carbapenemases were oxacillinase (OXA) 181 (23%), New Delhi metallo-β-lactamase (NDM) 5 (20%), OXA-48 (17%), Klebsiella pneumoniae carbapenemase 2 (15%), and NDM-1 (10%). We identified 5 dominant sequence types (STs); 4 were global (ST410, ST131, ST167, and ST405), and 1 (ST1284) was limited to Turkey. OXA-181 was frequent in Jordan (because of the ST410-B4/H24RxC subclade) and Turkey (because of ST1284). We found nearly identical IncX3-blaOXA-181 plasmids among 11 STs from 12 countries. NDM-5 was frequent in Egypt, Thailand (linked with ST410-B4/H24RxC and ST167-B subclades), and Vietnam (because of ST448). OXA-48 was common in Turkey (linked with ST11260). Global K. pneumoniae carbapenemases were linked with ST131 C1/H30 subclade and NDM-1 with various STs. The global carbapenemase E. coli population is dominated by diverse STs with different characteristics and varied geographic distributions, requiring ongoing genomic surveillance.

EID Peirano G, Chen L, Nobrega D, Finn TJ, Kreiswirth BN, DeVinney R, et al. Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015–2017. Emerg Infect Dis. 2022;28(5):924-931. https://doi.org/10.3201/eid2805.212535
AMA Peirano G, Chen L, Nobrega D, et al. Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015–2017. Emerging Infectious Diseases. 2022;28(5):924-931. doi:10.3201/eid2805.212535.
APA Peirano, G., Chen, L., Nobrega, D., Finn, T. J., Kreiswirth, B. N., DeVinney, R....Pitout, J. (2022). Genomic Epidemiology of Global Carbapenemase-Producing Escherichia coli, 2015–2017. Emerging Infectious Diseases, 28(5), 924-931. https://doi.org/10.3201/eid2805.212535.

Expires 3/22/2023
Medscape CME Activity
Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis [PDF - 2.53 MB - 11 pages]
K. Ogrinc et al.

Lyme neuroborreliosis (LNB) in Europe may manifest with painful meningoradiculoneuritis (also known as Bannwarth syndrome) or lymphocytic meningitis with or without cranial neuritis (peripheral facial palsy). We assessed host immune responses and the prevalence of TLR1 (toll-like receptor 1)–1805GG polymorphism to gain insights into the pathophysiology of these conditions. Regardless of LNB manifestation, most mediators associated with innate and adaptive immune responses were concentrated in cerebrospinal fluid; serum levels were unremarkable. When stratified by specific clinical manifestation, patients with meningoradiculoneuritis had higher levels of B-cell chemoattractants CXC motif chemokine ligand (CXCL) 12 and CXCL13 and T-cell–associated mediators CXCL9, CXCL10, and interleukin 17, compared with those without radicular pain. Moreover, these patients had a higher frequency of TLR1–1805GG polymorphism and more constitutional symptoms. These findings demonstrate that meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology, providing new considerations for the study of LNB and borrelial meningoradiculitis.

EID Ogrinc K, Hernández SA, Korva M, Bogovič P, Rojko T, Lusa L, et al. Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis. Emerg Infect Dis. 2022;28(4):766-776. https://doi.org/10.3201/eid2804.211831
AMA Ogrinc K, Hernández SA, Korva M, et al. Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis. Emerging Infectious Diseases. 2022;28(4):766-776. doi:10.3201/eid2804.211831.
APA Ogrinc, K., Hernández, S. A., Korva, M., Bogovič, P., Rojko, T., Lusa, L....Strle, K. (2022). Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis. Emerging Infectious Diseases, 28(4), 766-776. https://doi.org/10.3201/eid2804.211831.

Expires 3/17/2023
Medscape CME Activity
Shewanella spp. Bloodstream Infections in Queensland, Australia [PDF - 1.07 MB - 6 pages]
K. B. Laupland et al.

The epidemiology of bloodstream infections caused by Shewanella spp. is not well defined. Our objective was to define the incidence and determinants of Shewanella spp. bloodstream infections by using population-based surveillance in Queensland, Australia during 2000‒2019. The incidence was 1.0 cases/1 million persons annually and was highest during summer and in the tropical Torres and Cape region. Older persons and male patients were at highest risk. At least 1 concurrent condition was documented in 75% of case-patients, and 30-day all cause case-fatality rate was 15%. Aging populations in warm climates might expect an increasing burden of these infections.

EID Laupland KB, Stewart AG, Edwards F, Paterson DL, Coulter S, Heney C, et al. Shewanella spp. Bloodstream Infections in Queensland, Australia. Emerg Infect Dis. 2022;28(4):701-706. https://doi.org/10.3201/eid2804.212193
AMA Laupland KB, Stewart AG, Edwards F, et al. Shewanella spp. Bloodstream Infections in Queensland, Australia. Emerging Infectious Diseases. 2022;28(4):701-706. doi:10.3201/eid2804.212193.
APA Laupland, K. B., Stewart, A. G., Edwards, F., Paterson, D. L., Coulter, S., Heney, C....Harris, P. (2022). Shewanella spp. Bloodstream Infections in Queensland, Australia. Emerging Infectious Diseases, 28(4), 701-706. https://doi.org/10.3201/eid2804.212193.

Expires 2/17/2023
Medscape CME Activity
Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA [PDF - 984 KB - 9 pages]
R. A. Livingston et al.

Enterovirus D68 (EV-D68) causes severe respiratory illness outbreaks among children, particularly those with asthma. We previously detected neutralizing antibodies against the predominant EV-D68 B1 clade in the 2014 outbreak in serum collected before the outbreak (2012–2013) from persons 24 months to 85 years of age. We recently detected neutralizing antibodies to the 2014 B1, B2, and D clade viruses in serum collected after the 2014 outbreak (April–May 2017) from 300 children 6 months to 18 years of age. B1 virus neutralizing antibodies were found in 100% of patients, even children born after 2014; B2 in 84.6%, and D in 99.6%. In 2017, titers increased with patient age and were higher than titers in 2012–2013 from comparably aged children. Rate of seronegativity was highest (15.3%) for B2 virus. Multivariate analysis revealed an association between asthma and higher titers against B2 and D viruses. EV-D68 seems to have circulated during 2014–2017.

EID Livingston RA, Harrison CJ, Selvarangan R. Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA. Emerg Infect Dis. 2022;28(3):539-547. https://doi.org/10.3201/eid2803.211467
AMA Livingston RA, Harrison CJ, Selvarangan R. Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA. Emerging Infectious Diseases. 2022;28(3):539-547. doi:10.3201/eid2803.211467.
APA Livingston, R. A., Harrison, C. J., & Selvarangan, R. (2022). Neutralizing Enterovirus D68 Antibodies in Children after 2014 Outbreak, Kansas City, Missouri, USA. Emerging Infectious Diseases, 28(3), 539-547. https://doi.org/10.3201/eid2803.211467.

Expires 2/17/2023
Medscape CME Activity
Rising Incidence of Legionnaires’ Disease and Associated Epidemiologic Patterns, United States, 1992–2018 [PDF - 3.45 MB - 12 pages]
A. E. Barskey et al.

Reported Legionnaires’ disease (LD) cases began increasing in the United States in 2003 after relatively stable numbers for >10 years; reasons for the rise are unclear. We compared epidemiologic patterns associated with cases reported to the Centers for Disease Control and Prevention before and during the rise. The age-standardized average incidence was 0.48 cases/100,000 population during 1992–2002 compared with 2.71 cases/100,000 in 2018. Reported LD incidence increased in nearly every demographic, but increases tended to be larger in demographic groups with higher incidence. During both periods, the largest number of cases occurred among White persons, but the highest incidence was in Black or African American persons. Incidence and increases in incidence were generally largest in the East North Central, Middle Atlantic, and New England divisions. Seasonality was more pronounced during 2003–2018, especially in the Northeast and Midwest. Rising incidence was most notably associated with increasing racial disparities, geographic focus, and seasonality.

EID Barskey AE, Derado G, Edens C. Rising Incidence of Legionnaires’ Disease and Associated Epidemiologic Patterns, United States, 1992–2018. Emerg Infect Dis. 2022;28(3):527-538. https://doi.org/10.3201/eid2803.211435
AMA Barskey AE, Derado G, Edens C. Rising Incidence of Legionnaires’ Disease and Associated Epidemiologic Patterns, United States, 1992–2018. Emerging Infectious Diseases. 2022;28(3):527-538. doi:10.3201/eid2803.211435.
APA Barskey, A. E., Derado, G., & Edens, C. (2022). Rising Incidence of Legionnaires’ Disease and Associated Epidemiologic Patterns, United States, 1992–2018. Emerging Infectious Diseases, 28(3), 527-538. https://doi.org/10.3201/eid2803.211435.

CME Articles by Volume

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Coronavirus Spotlight

Spotlight Topics

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external